Table 4 Clinical response rate and pCR rate with different regimens
Variables | Radiographic response | ||||
|---|---|---|---|---|---|
CR/PR | SD/PD | RRa | P-value | pCR | |
All patients(n=82b) | 45 | 37 | 55% | Â | 5(6%) |
 gemcitabine | 24 | 21 | 53% |  | 2(4%) |
 paclitaxel | 18 | 11 | 62% | 0.309 | 3(10%) |
squamous (n=51) | 29 | 22 | 57% | Â | 4(8%) |
 gemcitabine | 18 | 14 | 56% |  |  |
 paclitaxel | 11 | 8 | 58% | 0.572 |  |
adenocarcinoma (n=29) | 15 | 14 | 52% | Â | 1(3%) |
 gemcitabine | 6 | 6 | 50% |  |  |
 paclitaxel | 6 | 3 | 67% |  |  |
 pemetrexed | 3 | 5 | 38% | 0.517 |  |